We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-7.79%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
+$7.74M
Cap. Flow
+$112M
Cap. Flow %
8.99%
Top 10 Hldgs %
54.36%
Holding
75
New
18
Increased
14
Reduced
16
Closed
18

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$51.7M
2
RVMD icon
Revolution Medicines
RVMD
+$44.9M
3
MRUS
Merus
MRUS
+$41.2M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$31.8M
5
IRON icon
Disc Medicine
IRON
+$31.4M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$58.5M
2
DYN icon
Dyne Therapeutics
DYN
+$42.6M
3
IMVT icon
Immunovant
IMVT
+$34.1M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$32.1M
5
GERN icon
Geron
GERN
+$29.7M

Sector Composition

Rank Sector Weight
1 Healthcare 69.8%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADVM
51
DELISTED
Adverum Biotechnologies
ADVM
$2.86M 0.23%
416,666
-1,083,333
-72% -$10.1M
APLT
52
DELISTED
Applied Therapeutics
APLT
$2.66M 0.21%
600,000
-750,000
-56% -$3.55M
RNAC icon
53
Cartesian Therapeutics
RNAC
$234M
$2.43M 0.2%
+90,000
New +$2.15M
UNCY icon
54
Unicycive Therapeutics
UNCY
$142M
$1.74M 0.14%
346,993
– –
IOBT
55
DELISTED
IO Biotech
IOBT
$578K 0.05%
493,827
– –
BOLD
56
Boundless Bio
BOLD
$55.7M
$433K 0.03%
117,806
-82,194
-41% -$786K
NUVB.WS
57
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$10.7K ﹤0.01%
66,666
– –
ALNY icon
58
CALL
Alnylam Pharmaceuticals
ALNY
$37.7B
– –
-500,000
Closed -$74.7M
ATXS
59
CALL
DELISTED
Astria Therapeutics
ATXS
– –
-1,000,000
Closed -$14.1M
CGEM icon
60
Cullinan Oncology
CGEM
$1.09B
– –
-700,000
Closed -$11.9M
CGON icon
61
CG Oncology
CGON
$6.36B
– –
-300,000
Closed -$13.2M
CLDX icon
62
Celldex Therapeutics
CLDX
$2.81B
– –
-650,000
Closed -$27.3M
CYTK icon
63
Cytokinetics
CYTK
$10.9B
– –
-100,000
Closed -$7.01M
GERN icon
64
Geron
GERN
$956M
– –
-9,000,000
Closed -$29.7M
IMCR icon
65
Immunocore
IMCR
$1.77B
– –
-900,000
Closed -$58.5M
IMTX icon
66
Immatics
IMTX
$1.26B
– –
-1,000,000
Closed -$10.5M
IMUX icon
67
Immunic
IMUX
$187M
– –
-42,118
Closed -$556K
KURA icon
68
Kura Oncology
KURA
$927M
– –
-300,000
Closed -$6.4M
CYPH
69
Cypherpunk Technologies Inc
CYPH
$69.2M
– –
-39,500
Closed -$105K
LRMR icon
70
CALL
Larimar Therapeutics
LRMR
$398M
– –
-700,000
Closed -$5.31M
PRAX icon
71
Praxis Precision Medicines
PRAX
$9.04B
– –
-150,000
Closed -$9.15M
SNDX icon
72
Syndax Pharmaceuticals
SNDX
$1.86B
– –
-350,000
Closed -$8.33M
TRML
73
DELISTED
Tourmaline Bio
TRML
– –
-99,208
Closed -$2.27M
VRDN icon
74
Viridian Therapeutics
VRDN
$2.2B
– –
-700,000
Closed -$12.3M
KYTX icon
75
Kyverna Therapeutics
KYTX
$489M
– –
-500,000
Closed -$12.4M
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q2 2024 Portfolio in Review

As of Q2 2024, Logos Global Management held 75 positions worth $1.24B, up 0.63% from $1.24B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Logos Global Management deployed $112M of net new capital in Q2 2024, opening 18 new positions and adding to 14 existing holdings. Its largest new stake was argenx: 135,000 shares worth $58.1M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 77% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Dyne Therapeutics, an estimated $42.6M trimmed.

  • Logos Global Management's largest Q2 2024 buy was argenx: 135,000 shares worth $58.1M.
  • Logos Global Management added most to Janux Therapeutics in Q2 2024, an estimated $28.2M increase.
  • Logos Global Management's biggest Q2 2024 reduction was Dyne Therapeutics, cutting an estimated $42.6M.
  • Logos Global Management fully exited Immunocore in Q2 2024, selling an estimated $58.5M.
  • Logos Global Management's ten largest holdings make up 54% of its $1.24B portfolio in Q2 2024.
  • Logos Global Management opened 18 new positions and closed 18 in Q2 2024.
  • Logos Global Management's portfolio value rose 0.63% quarter-over-quarter to $1.24B.

Based on Logos Global Management's 13F filing for Q2 2024, filed 14 Aug 2024.